Revision as of 15:07, 13 April 2015 by Aparna Vuppala (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Clinical data
AHFS/Drugs.comInternational Drug Names
  • X
Routes of
Oral, Intravaginal
ATC code
Pharmacokinetic data
ExcretionRenal, fecal
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass308.41 g/mol
3D model (JSmol)

WikiDoc Resources for Gestrinone


Most recent articles on Gestrinone

Most cited articles on Gestrinone

Review articles on Gestrinone

Articles on Gestrinone in N Eng J Med, Lancet, BMJ


Powerpoint slides on Gestrinone

Images of Gestrinone

Photos of Gestrinone

Podcasts & MP3s on Gestrinone

Videos on Gestrinone

Evidence Based Medicine

Cochrane Collaboration on Gestrinone

Bandolier on Gestrinone

TRIP on Gestrinone

Clinical Trials

Ongoing Trials on Gestrinone at Clinical

Trial results on Gestrinone

Clinical Trials on Gestrinone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Gestrinone

NICE Guidance on Gestrinone


FDA on Gestrinone

CDC on Gestrinone


Books on Gestrinone


Gestrinone in the news

Be alerted to news on Gestrinone

News trends on Gestrinone


Blogs on Gestrinone


Definitions of Gestrinone

Patient Resources / Community

Patient resources on Gestrinone

Discussion groups on Gestrinone

Patient Handouts on Gestrinone

Directions to Hospitals Treating Gestrinone

Risk calculators and risk factors for Gestrinone

Healthcare Provider Resources

Symptoms of Gestrinone

Causes & Risk Factors for Gestrinone

Diagnostic studies for Gestrinone

Treatment of Gestrinone

Continuing Medical Education (CME)

CME Programs on Gestrinone


Gestrinone en Espanol

Gestrinone en Francais


Gestrinone in the Marketplace

Patents on Gestrinone

Experimental / Informatics

List of terms related to Gestrinone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Gestrinone is a synthetic steroid with mixed progestogen and antiprogestogen (i.e., partial agonist) effects, and also has some mild androgenic activity.[1] It is marketed under the names Dimetriose, Dimetrose, and Nemestran, as a treatment for endometriosis. Gestrinone is available in many countries, but not in the USA. As it has anabolic effects, its use in competition has been banned by the International Olympic Committee.[2]

Method of action

Its mechanism of action consists of suppression of the release of pituitary gonadotropins. Gestrinone also interacts with the endometrium, inhibiting its growth. The inhibition is the result of gestrinone's interaction with the androgen receptor; this is also the reason for androgenic side effects. Gestrinone has been shown to interact with the estrogen receptor, the androgen receptor, and the progesterone receptor.[3]


The drug is well absorbed via the oral route, passed through the liver, and has a half-life of about 24 hours. It is metabolized by the liver and excreted by urine and feces.

Contraindications and side effects

The drug is contraindicated in pregnancy, during lactation, and in patients with severe cardiac, renal or hepatic insufficiency. It is also contraindicated in patients who experienced metabolic and/or vascular disorders during previous estrogen or progestogen therapy, or who are allergic to the medication. The drug is contraindicated in children.

Side effects include vaginal spotting, and, in susceptible individuals, signs of increased androgen activity such as acne, oily skin, fluid retention, weight gain, hirsutism, voice change, or hair loss.

Other uses

The drug has also been investigated for use as a prospective contraceptive agent and as a postcoital contraceptive.[4] It also has been used to shrink uterine fibroids and to reduce menorrhagia[5][6]

Its androgenic properties are more exploited in a "designer steroid", the derivative tetrahydrogestrinone. THG was banned by the Food and Drug Administration (FDA) in 2003.


  1. Bromham, D. R.; Booker, M. W.; Rose, Gillian; Wardle, P. G.; Newton, J. R. (1995). "A multicentre comparative study of gestrinone and danazol in the treatment of endometriosis". Journal of Obstetrics and Gynaecology. 15 (3): 188–194. doi:10.3109/01443619509015498. ISSN 0144-3615.
  2. "Helping athletes compete drug-free" (PDF). Canadian Centre for Ethics in Sport. May 2000. p. 34. Archived from the original (PDF) on 2006-05-17. Retrieved 2006-06-01.
  3. Tamaya, T. (1986). "Gestrinone (R2323) binding to steroid receptors in human uterine endometrial cytosol". Acta obstetricia et gynecologica Scandinavica. 65 (5): 439–41. doi:10.3109/00016348609157380. PMID 3490730. Unknown parameter |coauthors= ignored (help); |access-date= requires |url= (help)
  4. "Emergency Contraception Update". International Consortium for Emergency Contraception. October 2006. p. 5. Archived from the original (RTF) on 2006-06-20. Retrieved 2006-06-01.
  5. La Marca, A. (December 2004). "Gestrinone in the treatment of uterine leiomyomata: effects on uterine blood supply". Fertility and Sterility. 82 (6): 1694–6. doi:10.1016/j.fertnstert.2004.08.004. PMID 15589885. Unknown parameter |coauthors= ignored (help); |access-date= requires |url= (help)
  6. Roy, SN.; Bhattacharya S. (2004). "Benefits and risks of pharmacological agents used for the treatment of menorrhagia". Drug safety : an international journal of medical toxicology and drug experience. 27 (2): 75–90. doi:10.2165/00002018-200427020-00001. PMID 14717620. |access-date= requires |url= (help)